TMCI - Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023 | Benzinga
PONTE VEDRA, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ clinical study at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2023 in Louisville, Kentucky from September 20-23, 2023.
"As the industry's only company solely focused on advancing the standard of care in the surgical correction of bunion and related midfoot deformities, we are excited to feature our latest R&D innovations to surgeons attending the 2023 AOFAS conference," stated John T. Treace, CEO, Founder and Board Member of Treace. "Our new SpeedPlate™ and Micro-Lapiplasty™ technologies demonstrate Treace's commitment to rapid innovation with a focus on continually iterating the Lapiplasty® System with options for increased procedural efficiency and reduced incision size associated with the Lapiplasty® Procedure."
Mr. Treace continued, "Interim data readouts from our ongoing ALIGN3D™ clinical study continue to demonstrate sustained, successful procedural and patient outcomes on additional patients followed through 36- and 48-months post-procedure. We are proud to continue our commitment to investing in clinical studies and expanding the differentiated body of clinical evidence to advance the Lapiplasty® Procedure as the standard of care for bunion surgery."
Several technologies will be highlighted at Treace's booth at the AOFAS conference, including:
- SpeedPlate™ Implant Fixation Platform: This new platform of Lapiplasty® fixation technology is designed for rapid insertion while providing dynamic compression of the joint surfaces. Since it can be implanted through a small 2cm incision, the SpeedPlate™ technology not only offers broad applicability with the Company's standard Lapiplasty® and Adductoplasty® systems, but also serves as the enabling fixation technology for our Micro-Lapiplasty™ system. Full commercial launch of the SpeedPlate™ technology is anticipated in the fourth quarter of this year.
- Micro-Lapiplasty™ Minimally Invasive System: This advanced instrumentation option is designed to further reduce the incision size and related tissue dissection with the Lapiplasty® procedure. The advanced instrument set, including the Micro-Lapiplasty™ 3-n-1™ Guide and other specialized surgical instruments, allows the deformity correction and joint preparation steps of the patented Lapiplasty® Procedure to be performed through a 2cm incision. The Micro-Lapiplasty™ System is currently in limited clinical release with full commercial launch expected in the fourth quarter of this year.
- New Lapiplasty® Innovations: Recently commercialized innovations, including the LapiTome™ and ...